Seaport Therapeutics, INC
Market Movers (8-K)
NASDAQ
Seaport Therapeutics announced its second quarter 2026 financial results, detailing progress in its clinical trials for major depressive disorder and generalized anxiety disorder, alongside a robust cash position post-IPO.
Capital raise
Quarterly Earnings (10-Q)
NASDAQ
Seaport Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing increased R&D expenses and substantial operating losses, while noting sufficient cash runway into 2029.
Capital raise
Worse than expected
Insider Trading (Form 4)
NASDAQ
Seaport Therapeutics Director Robert J. Hombach acquired 13,000 shares of common stock in a transaction on June 22, 2026.